Canada Cannabidiol Market Overview,2030

Long before cannabidiol arrived in wellness shops, Canada’s relationship with cannabis stretches back decades, as medical access was permitted under the Marihuana for Medical Purposes Regulations in 2001, allowing patients to use dried flower and oils under licence, now since the passing of the Cannabis Act in 2018 the environment for cannabidiol extracts has become far more structured under Health Canada oversight. Licensed industrial hemp producers may grow varieties approved by Health Canada’s List of Approved Cultivars and are able to sell non‑viable seeds and certain seed derivatives containing extremely low THC levels, while processors holding cannabis processing licences may extract cannabidiol from the flowering parts under strict regulatory conditions. Packaging rules require plain, uniform colouring, child resistance and tamper evidence, labelling must include cannabinoid content and lot numbers, and third‑party testing for contaminants like heavy metals, microbes or residual solvents is enforced. Stakeholders recently received a consultation paper in 2025 proposing that over‑the‑counter products containing cannabidiol be regulated under the Natural Health Products Regulations, which would allow non‑prescription access under conditions similar to vitamins or herbal remedies. Meanwhile research from the Science Advisory Committee has highlighted gaps in long‑term safety data for high daily doses of cannabidiol, especially in seniors or those taking concurrent medications. Canada’s regulatory regime has also introduced amendments streamlining licence classes (e.g. micro‑processing, analytical testing permissions) and reducing burdens for applicants under the March 12, 2025 updates, thereby encouraging competition among producers.

According to the research report, ""Canada Cannabidiol Market Overview, 2030,"" published by Bonafide Research, the Canada Cannabidiol market is expected to reach a market size of more than USD 1.25 Billion by 2030. Within Canada the cannabidiol space is marked by opportunity and regulatory friction, established firms such as Tilray Brands, Aurora Cannabis, and Organigram Holdings continue to lead in output of oils and extracts, while newer companies are pushing into topical creams and personalized formulations. Provincial retail regimes like those in Ontario under the AGCO, British Columbia’s LCRB and Alberta’s AGLC have shaped how legal recreational cannabidiol products are sold and which stores may carry them, e‑commerce also plays an important role with federally authorised retailers able to ship into provinces permitting legal adult‑use cannabis retail. Marketing is tightly regulated, Health Canada prohibits unverified health claims, so many brands use educational content, published research, or third‑party lab results rather than promise effects. Social media platforms are used heavily for awareness building, though Content Policies limit promotional claims. Supply chain challenges include securing hemp biomass compliant with THC limit 0.3% and obtaining processing licences, some processors report delays with obtaining requisite licences, especially for micro‑processors. Branding differentiators include full spectrum extracts retaining minor cannabinoids and terpenes, nanoemulsion formats aimed at faster absorption in oils or beverages, and use of sustainable packaging materials. Consumer preference trends show increasing demand for transparent sourcing, precision in labelling of CBD and THC amounts, and assurance of quality via accredited laboratories. Legal uncertainty remains for non‑prescription cannabidiol products under Natural Health Products Regulations, though proposed amendments aim to clarify pathways, meanwhile veterinary cannabidiol use is being explored, with Health Canada drafting possible regulation for animal health products.

In Canada, oils & tinctures remain foundational to the CBD product landscape, especially in provinces such as British Columbia, Ontario, and Quebec where many licensed producers offer full‑spectrum and broad‑spectrum cannabinoid extracts in dropper bottles that users dose under the tongue, in British Columbia many small craft cannabis producers channel their hemp extract into tinctures, while in Ontario consumers buying from provincial cannabis retail chains often find CBD oils alongside THC oils. Capsules & softgels are less common but are seen in medical cannabis prescription services in cities like Toronto and Vancouver, where patients prefer standardized dosing and easy swallowing format, sometimes packaged in blister packs for stability. Gummies & confectionery are part of the edible options available through regulated cannabis retailers in Alberta and Saskatchewan, often offered in small pack sizes with controlled CBD content to comply with provincial limits. Topicals / skin care items such as balms, lotions, creams, serums and massage oils are sold in wellness‑oriented cannabis dispensaries and authorized cannabis stores in Calgary, Edmonton, Montreal, and Halifax for consumers who seek topical relief for pain, muscle soreness, or skin inflammation without ingestion. Vape products containing CBD (in cartridge or pod formats) exist in provinces where vaping is permitted under cannabis retail operations, for instance in Manitoba or Nova Scotia, though some provincial regulators impose stricter rules on inhalable cannabis products. The others categories include formats such as oral sprays, dissolvable strips, transdermal patches, and even CBD‑infused beverages which are occasionally offered in licensed cannabis cafés in Vancouver or pilot stores in Ontario, these alternative formats cater to niche users looking for fast onset or discreet delivery methods beyond oils, capsules, topicals, or vapes.

Within Canada, many individuals use cannabidiol for wellness & personal use, particularly in urban centers such as Vancouver, Toronto, and Montreal where health‑conscious consumers incorporate CBD tinctures or low‑dose oils into morning or evening routines to support balance, stress relief, or sleep without needing a medical authorization. In the nutraceuticals & supplements space, CBD is slowly emerging in parallel to traditional botanical supplements in provinces like Alberta and British Columbia, with some licensed cannabis firms exploring formulations that mimic dietary supplement style dosing, though under Canada’s current regulatory regime CBD must remain under the cannabis rules. In the pet care segment, Canadian pet owners across Ontario, Saskatchewan, and Nova Scotia purchase pet‑safe CBD drops or chews formulated specifically for dogs and cats, with some veterinary clinics in cities such as Calgary or Halifax carrying THC‑free CBD pet products for anxiety or joint health in animals. Under cosmetics & skin care, Canadian manufacturers based in British Columbia and Quebec incorporate CBD into facial serums, body lotions, bath oils, and beauty masks that are available in licensed cannabis retail locations or specialty boutiques, these products appeal to consumers seeking anti‑inflammatory or soothing topical effects. In pharmaceuticals, Canada is unique in that there is at least one federally approved CBD‑based drug which must be dispensed through pharmacies or authorized medical channels under Health Canada’s oversight, and patients in provinces like Ontario or Quebec who qualify for prescription cannabis may receive CBD formulations delivered via licensed medical distributors. Finally in food & beverages, though full commercialization of CBD edibles faces regulatory constraints in Canada, some pilot programs and licensed cannabis retailers in Ontario and British Columbia permit limited CBD‑infused beverages, energy drinks, or sodas sold in licensed cannabis stores to adult consumers under strict packaging and dosage rules, offering a taste‑based route for consuming CBD beyond pills and oils.

In Canada, marijuana‑derived cannabidiol comes from cannabis plants cultivated under licenses that allow both CBD and higher THC content, typically used in provinces with legal recreational cannabis, licensed producers in Ontario, Alberta, and British Columbia cultivate strains rich in both CBD and THC, process whole plant extracts, and supply dispensaries or cannabis retailers in cities like Toronto, Calgary, and Vancouver with products in which CBD is derived alongside THC. Hemp‑derived cannabidiol in Canada is produced under industrial hemp regulations that permit hemp plants with very low THC content, hemp farms in provinces like Saskatchewan, Manitoba, and Quebec grow hemp varieties within the legal THC limit and sell harvested biomass to licensed processor facilities, many located near Montreal or Quebec City, which extract CBD and convert it into distillates or isolate forms for use in consumer CBD offerings. Hemp‑derived CBD tends to feed non‑intoxicating consumer products because it avoids higher THC levels, and it is these hemp‑based extracts that are most widely used in everyday oils, topicals, and wellness products across Canadian cannabis retail outlets. Under Canada’s Cannabis Act, hemp‑derived CBD is regulated similarly to other cannabis products, so whether the source is marijuana or hemp the product must conform to the same licensing, quality, packaging, and sale rules to reach Canadian consumers legally.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Cannabidiol Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Form
• Oils & Tinctures
• Capsules & Softgels
• Gummies & Confectionery
• Topicals / Skin Care
• Vape Products
• Others

By End Use
• Wellness & Personal Use
• Nutraceuticals & Supplements
• Pet Care
• Cosmetics & Skin Care
• Pharmaceuticals
• Food & Beverages

By Source
• Marijuana
• Hemp Show more